DNA quantification Human

Get tips on using CD163 Monoclonal Antibody (eBioGHI/61 (GHI/61)), eBioscience™ to perform Flow cytometry Anti-bodies Human - CD163

Get tips on using FOXP3 Monoclonal Antibody (PCH101), Alexa Fluor 700, eBioscience™ to perform Flow cytometry Anti-bodies Human - FOXP3

Get tips on using CD4 Monoclonal Antibody (OKT4 (OKT-4)), FITC, eBioscience™ to perform Flow cytometry Anti-bodies Human - CD4

Get tips on using CD133 (Prominin-1) Monoclonal Antibody (13A4), APC, eBioscience™ to perform Flow cytometry Anti-bodies Human - CD133

Get tips on using Aurum™ Total RNA Fatty and Fibrous Tissue Kit to perform RNA isolation / purification Tissue - Human Uterus

Get tips on using Aurum™ Total RNA Fatty and Fibrous Tissue Kit to perform RNA isolation / purification Tissue - Human Adipose

Get tips on using In Situ Cell Death Detection Kit, TMR red to perform TUNEL assay cell type - A549, NCI-H460, H1299 human lung cancer cells

Get tips on using NEBNext® Multiplex Small RNA Library Prep Set for Illumina® to perform RNA sequencing Human - HEK293T

The RNA-guided CRISPR-Cas9 nuclease system has revolutionized the genome editing practices. For the most part, the Cas9-mediated genome editing is performed either via nonhomologous end joining (NHEJ) or homology-directed repair (HDR) in mammalian cells, However, designing of specific sgRNAs and minimizing off-target cleavage mediated mutagenesis are the major challenges in CRISPR-Cas based genome editing. To circumvent these issues, we can take advantages of many available tools and approaches for sgRNA construction and delivery.

The RNA-guided CRISPR-Cas9 nuclease system has revolutionized the genome editing practices. For the most part, the Cas9-mediated genome editing is performed either via nonhomologous end joining (NHEJ) or homology-directed repair (HDR) in mammalian cells, However, designing of specific sgRNAs and minimizing off-target cleavage mediated mutagenesis are the major challenges in CRISPR-Cas based genome editing. To circumvent these issues, we can take advantages of many available tools and approaches for sgRNA construction and delivery.